Overview News About Filings Financials Attachments
CRDL price & chart Provider market data
TradingView · Data may be delayed
About the company Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular innate immune system response known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.
6-K · 2026-09-23 · 0001279569-26-000905
Company description from the cited filing.
In the news No coverage from other publishers is available.
Seeking Alpha Seeking Alpha · 2026-09-16
Seeking Alpha · 2026-09-12
Seeking Alpha · 2026-09-11
Financials FY 2025 · CAD Revenue — · FY 2025 Net income — · FY 2025 Assets — CAD · FY 2025 Cash — · FY 2025 Operating income -34,316,296 CAD · FY 2025 Source 40-F · 2026-03-31 · 0001104659-26-037844
2025-01-01 to 2025-12-31
Diluted EPS -0.39 CAD/shares · FY 2025 Source 40-F · 2026-03-31 · 0001104659-26-037844
2025-01-01 to 2025-12-31
Some figures are unavailable for this reporting year.
Balance-sheet figures are unavailable pending verification.
cash flow · annual statements Line item FY 2025 FY 2024 FY 2023 FY 2022 Cash flows from operating activities: Profit or Loss CAD -33,818,874Source 40-F · 2026-03-31 · 0001104659-26-037844
2025-01-01 to 2025-12-31
-36,677,299Source 40-F · 2025-03-31 · 0001410578-25-000588
2024-01-01 to 2024-12-31
-28,128,292Source 20-F · 2024-04-01 · 0001104659-24-041952
2023-01-01 to 2023-12-31
-30,930,647Source 20-F · 2023-03-29 · 0001104659-23-037820
2022-01-01 to 2022-12-31
Additional Financial Items AdjustmentsForDecreaseIncreaseInTradeAccountReceivableCAD 44,639Source 40-F · 2026-03-31 · 0001104659-26-037844
2025-01-01 to 2025-12-31
42,379Source 40-F · 2025-03-31 · 0001410578-25-000588
2024-01-01 to 2024-12-31
67,178Source 20-F · 2024-04-01 · 0001104659-24-041952
2023-01-01 to 2023-12-31
-144,184Source 20-F · 2023-03-29 · 0001104659-23-037820
2022-01-01 to 2022-12-31
AdjustmentsForSharebasedPaymentsCAD 10,700,913Source 40-F · 2026-03-31 · 0001104659-26-037844
2025-01-01 to 2025-12-31
14,277,406Source 40-F · 2025-03-31 · 0001410578-25-000588
2024-01-01 to 2024-12-31
4,156,762Source 20-F · 2024-04-01 · 0001104659-24-041952
2023-01-01 to 2023-12-31
5,013,185Source 20-F · 2023-03-29 · 0001104659-23-037820
2022-01-01 to 2022-12-31
GeneralAndAdministrativeExpenseCAD 20,297,835Source 40-F · 2026-03-31 · 0001104659-26-037844
2025-01-01 to 2025-12-31
26,264,521Source 40-F · 2025-03-31 · 0001410578-25-000588
2024-01-01 to 2024-12-31
15,561,217Source 20-F · 2024-04-01 · 0001104659-24-041952
2023-01-01 to 2023-12-31
22,373,798Source 20-F · 2023-03-29 · 0001104659-23-037820
2022-01-01 to 2022-12-31
PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesCAD 55,376Source 40-F · 2026-03-31 · 0001104659-26-037844
2025-01-01 to 2025-12-31
41,532Source 40-F · 2025-03-31 · 0001410578-25-000588
2024-01-01 to 2024-12-31
55,376Source 20-F · 2024-04-01 · 0001104659-24-041952
2023-01-01 to 2023-12-31
53,934Source 20-F · 2023-03-29 · 0001104659-23-037820
2022-01-01 to 2022-12-31
ProceedsFromIssuingSharesCAD 16,037,974Source 40-F · 2026-03-31 · 0001104659-26-037844
2025-01-01 to 2025-12-31
21,355,588Source 40-F · 2025-03-31 · 0001410578-25-000588
2024-01-01 to 2024-12-31
— —
Lines labelled “Derived” are calculated from reported figures.
income statement · annual statements Line item FY 2025 FY 2024 FY 2023 FY 2022 Additional Financial Items ApplicableTaxRatenumber 0.27Source 40-F · 2026-03-31 · 0001104659-26-037844
2025-01-01 to 2025-12-31
0.27Source 40-F · 2025-03-31 · 0001410578-25-000588
2024-01-01 to 2024-12-31
0.27Source 20-F · 2024-04-01 · 0001104659-24-041952
2023-01-01 to 2023-12-31
0.27Source 20-F · 2023-03-29 · 0001104659-23-037820
2022-01-01 to 2022-12-31
BasicEarningsLossPerShareCAD/shares -0.39Source 40-F · 2026-03-31 · 0001104659-26-037844
2025-01-01 to 2025-12-31
-0.51Source 40-F · 2025-03-31 · 0001410578-25-000588
2024-01-01 to 2024-12-31
-0.44Source 20-F · 2024-04-01 · 0001104659-24-041952
2023-01-01 to 2023-12-31
-0.49Source 20-F · 2023-03-29 · 0001104659-23-037820
2022-01-01 to 2022-12-31
DilutedEarningsLossPerShareCAD/shares -0.39Source 40-F · 2026-03-31 · 0001104659-26-037844
2025-01-01 to 2025-12-31
-0.51Source 40-F · 2025-03-31 · 0001410578-25-000588
2024-01-01 to 2024-12-31
-0.44Source 20-F · 2024-04-01 · 0001104659-24-041952
2023-01-01 to 2023-12-31
-0.49Source 20-F · 2023-03-29 · 0001104659-23-037820
2022-01-01 to 2022-12-31
GeneralAndAdministrativeExpenseCAD 20,297,835Source 40-F · 2026-03-31 · 0001104659-26-037844
2025-01-01 to 2025-12-31
26,264,521Source 40-F · 2025-03-31 · 0001410578-25-000588
2024-01-01 to 2024-12-31
15,561,217Source 20-F · 2024-04-01 · 0001104659-24-041952
2023-01-01 to 2023-12-31
22,373,798Source 20-F · 2023-03-29 · 0001104659-23-037820
2022-01-01 to 2022-12-31
ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillCAD — — 0Source 20-F · 2024-04-01 · 0001104659-24-041952
2023-01-01 to 2023-12-31
— IncomeTaxExpenseContinuingOperationsCAD — — — 0Source 20-F · 2023-03-29 · 0001104659-23-037820
2022-01-01 to 2022-12-31
OtherIncomeCAD — 28,223Source 40-F · 2025-03-31 · 0001410578-25-000588
2024-01-01 to 2024-12-31
149,739Source 20-F · 2024-04-01 · 0001104659-24-041952
2023-01-01 to 2023-12-31
164,443Source 20-F · 2023-03-29 · 0001104659-23-037820
2022-01-01 to 2022-12-31
ProfitLossFromOperatingActivitiesCAD -34,316,296Source 40-F · 2026-03-31 · 0001104659-26-037844
2025-01-01 to 2025-12-31
-40,276,651Source 40-F · 2025-03-31 · 0001410578-25-000588
2024-01-01 to 2024-12-31
-29,785,504Source 20-F · 2024-04-01 · 0001104659-24-041952
2023-01-01 to 2023-12-31
-41,335,878Source 20-F · 2023-03-29 · 0001104659-23-037820
2022-01-01 to 2022-12-31
ResearchAndDevelopmentExpenseCAD 14,018,461Source 40-F · 2026-03-31 · 0001104659-26-037844
2025-01-01 to 2025-12-31
14,012,130Source 40-F · 2025-03-31 · 0001410578-25-000588
2024-01-01 to 2024-12-31
14,224,287Source 20-F · 2024-04-01 · 0001104659-24-041952
2023-01-01 to 2023-12-31
18,962,080Source 20-F · 2023-03-29 · 0001104659-23-037820
2022-01-01 to 2022-12-31
RevenueFromInterestCAD 726,401Source 40-F · 2026-03-31 · 0001104659-26-037844
2025-01-01 to 2025-12-31
1,193,342Source 40-F · 2025-03-31 · 0001410578-25-000588
2024-01-01 to 2024-12-31
2,038,465Source 20-F · 2024-04-01 · 0001104659-24-041952
2023-01-01 to 2023-12-31
1,237,632Source 20-F · 2023-03-29 · 0001104659-23-037820
2022-01-01 to 2022-12-31
Lines labelled “Derived” are calculated from reported figures.
Filing attachments ex991.htm · 6-K · 2026-09-23 EXHIBIT 99.1
Cardiol Therapeutics Achieves Phase III MAVERIC
Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy
Original 110-patient enrollment target achieved ahead of the Company's
end-of-September guidance.
The MAVERIC Steering Committee recommends expanding enrollment
to up to 150 patients to capture sufficient events for a robust assessment of CardiolRx™'s potential to reduce recurrence risk.
The recommendation follows a blinde…
6-K · 2026-09-23 · 0001279569-26-000905
Read attachment ↗